On Oct 31, major Wall Street analysts update their ratings for $Biogen (BIIB.US)$, with price targets ranging from $190 to $315.
Morgan Stanley analyst Terence Flynn downgrades to a hold rating, and adjusts the target price from $285 to $204.
Goldman Sachs analyst Salveen Richter maintains with a buy rating, and adjusts the target price from $320 to $290.
BofA Securities analyst Jason Zemansky initiates coverage with a hold rating, and sets the target price at $250.
Wells Fargo analyst Mohit Bansal maintains with a hold rating, and adjusts the target price from $225 to $190.
Jefferies analyst Michael Yee maintains with a buy rating, and maintains the target price at $250.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
Post-Q3 report observations indicate that the company's product launches continue to face challenges amidst escalating competitive dynamics. Additionally, the emerging pipeline catalysts for the firm are anticipated to mature mainly in 2026 and subsequent years.
The launch of Leqembi has been underperforming against expectations, coupled with a perceived constrained pipeline potential in the forthcoming year. There's an acknowledgment of an initial underestimation of the reimbursement and logistical challenges faced by Leqembi. A neutral stance is now being taken on Biogen, with a cautious perspective on lecanemab's progress.
Biogen's strong Q3 financial performance, with total revenue surpassing estimates and adjusted EPS also exceeding expectations, highlights the company's robust results. The firm acknowledges that the sales performance of Leqembi is ahead of consensus, indicating solid momentum in infrastructure development. It is expected that the introduction of IV maintenance and subQ forms will substantially enhance adoption in 2025.
Biogen's recent performance showcased quarterly revenue that met expectations and an earnings per share that exceeded forecasts. The company's future earnings guidance has been adjusted upward. The rollout of Leqembi is gathering pace, although logistical and capacity challenges persist as obstacles to its widespread adoption.
Here are the latest investment ratings and price targets for $Biogen (BIIB.US)$ from 13 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$渤健公司 (BIIB.US)$的評級，目標價介於190美元至315美元。
摩根士丹利分析師Terence Flynn下調至持有評級，並將目標價從285美元下調至204美元。
高盛集團分析師Salveen Richter維持買入評級，並將目標價從320美元下調至290美元。
美銀證券分析師Jason Zemansky首次給予持有評級，目標價250美元。
富國集團分析師Mohit Bansal維持持有評級，並將目標價從225美元下調至190美元。
富瑞集團分析師Michael Yee維持買入評級，維持目標價250美元。
此外，綜合報道，$渤健公司 (BIIB.US)$近期主要分析師觀點如下：
發帖-Q3報告觀察到，公司的新品發佈仍在不斷面臨競爭加劇的挑戰。此外，公司預計主要在2026年及以後年份迎來新的產業鏈催化劑的成熟。
Leqembi的推出表現低於預期，並且在即將到來的一年中，受制於管道潛力有限的認知。對Leqembi面臨的報銷和後勤挑戰的初始低估有所認識。現在對渤健公司採取中立立場，對lecanemab的進展持謹慎態度。
渤健公司強勁的Q3財務表現，總營業收入超出預期，調整後每股收益也超出預期，突顯出公司的強勁業績。公司承認Leqembi的銷售表現領先於共識，表明製造行業發展勢頭良好。預計IV維護和subQ形式的引入將在2025年大幅提升採用率。
渤健公司最近的業績展示出符合預期的季度營業收入和超過預測的每股收益。公司未來的收益指引已經上調。Leqembi的推出正加速進行，儘管後勤和產能挑戰仍然是普遍採用的障礙。
以下爲今日13位分析師對$渤健公司 (BIIB.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
